Health and Me

Ishita Roy

India’s First Dengue Vaccine Nears Final Trial Stage

In a significant stride toward curbing the spread of vector-borne diseases, India is moving closer to having its first indigenous <span><a href="https://www.healthandme.com/health/dengue">dengue</a></span> vaccine. The Indian Council of Medical Research (ICMR), in collaboration with Panacea Biotec, is on track to complete the enrollment of participants for Phase 3 clinical trials by October 2025, according to CNBC-TV18.

This crucial phase of testing, launched on August 14, 2024, marks the most advanced stage yet for the vaccine’s development. The multi-center, double-blind, randomised, placebo-controlled study is designed to assess the vaccine’s efficacy, safety, and long-term immunogenicity. So far, over 70% of the targeted 10,335 participants have been enrolled across 20 medical centers nationwide, according to CNBC-TV18 sources.

<h4>Two-Year Follow-Up Required Before Regulatory Submission</h4>

Once participant enrollment is completed, each subject will be monitored for a two-year follow-up period. This extended observation window, considered critical for evaluating the vaccine's long-term safety and effectiveness, is expected to conclude by the end of 2027.

According to CNBC-TV18, sources familiar with the development confirmed, “The enrollment process is progressing smoothly, and no safety concerns have been reported so far.”

Only after the follow-up period ends and the data are thoroughly analyzed will the findings be submitted to the Central Drugs Standard Control Organization (CDSCO) for regulatory review and potential market authorization. “If the vaccine demonstrates acceptable efficacy and a clean safety profile, it could then be considered for regulatory approval and subsequent launch,” CNBC-TV18 reported, quoting official sources.

<strong>ALSO READ: <a href="https://www.healthandme.com/health-wellness/national-dengue-day-2025-dengue-on-the-rise-how-climate-and-geography-are-shaping-a-growing-threat-article-151651192" data-type="tilCustomLink">Dengue On The Rise: How Climate And Geography Are Shaping A Growing Threat</a></strong>

<h4>National-Scale Trial Across Premier Institutions</h4>

The Phase 3 trial is being carried out at reputed medical institutions located in major cities including Chennai, Pune, Hyderabad, Bengaluru, New Delhi, and Kolkata. According to CNBC-TV18, the study protocol stipulates a comprehensive two-year post-vaccination follow-up. The final data from this period will be crucial in determining the vaccine’s fate in the Indian market.

<h4>A Single-Dose Vaccine: What Is It All About?</h4>

What sets this vaccine apart from global counterparts is its single-dose formulation. This is expected to ease the logistical and financial challenges of mass immunization in dengue-endemic areas. Unlike international vaccines like Sanofi’s Dengvaxia and Takeda’s QDENGA—which require multiple doses and have limitations in efficacy across different dengue virus serotypes—India’s homegrown candidate offers a potentially more accessible and broadly applicable alternative.

Earlier phases of clinical evaluation, including Phase 1 and Phase 2 trials conducted in India, had already received regulatory clearance from CDSCO. These trials showed that the vaccine was both safe and capable of eliciting a strong immune response.

“India’s first dengue vaccine candidate has shown encouraging results so far. Phase 1 and 2 trials confirmed that the vaccine is safe and induces a protective immune response. We’re hopeful that Phase 3 will bring us closer to a much-needed tool in dengue prevention,” CNBC-TV18 reported, citing official sources.

<strong>YOU MAY LIKE: <a href="https://www.healthandme.com/health-news/dengiall-indias-first-indigenous-dengue-vaccine-nears-completion-set-to-hit-markets-by-next-year-article-151435802" data-type="tilCustomLink">India’s First Indigenous Dengue Vaccine Coming Soon; What To Expect?</a></strong>

<h4>A Vital Step for a Country with High Dengue Burden</h4>

India continues to suffer from seasonal dengue outbreaks, with thousands of hospitalizations each year placing strain on public health infrastructure. The World Health Organization estimates about 390 million dengue infections occur globally each year, with India accounting for a significant portion. With no specific antiviral treatment available, prevention through vaccination and vector control remains the most effective strategy.

As per current projections, enrollment will wrap up by October 2025, followed by a two-year follow-up until the end of 2027. Only after this can ICMR and Panacea Biotec submit their formal application for market authorization, CNBC-TV18 noted.

If the vaccine passes regulatory scrutiny, it could revolutionize dengue control efforts not only in India but also in other low- and middle-income countries grappling with high disease burdens and limited access to effective vaccines.

Health Conditions A-Z

health

dengue vaccine india

health news

health news india

india news health

indian dengue vaccine

dengue

Kang Seo-ha, South Korean Actress Dies At 31 After Battling Stage IV Stomach cancer

Australia Sees Rise In Meningococcal Disease: What You Need To Know About Symptoms And Vaccination

Over 14 Million Children Miss Out On Vaccines Amid Aid Cuts And Rising Misinformation

Health News

Yoga Poses That Can Help With Bloating

Fiber-Rich Oatmeal Dishes You Can Have For Breakfast

Signs You Must Visit A Doctor For Your Back Pain

Avocado Meal Prep Ideas To Increase Healthy Fat In Your Diet

Arm Exercises You Can Do At Home

Quick-Office Lunches That Can Keep You Full-Longer

How Increased Screen Time Affects Children's Health

Homemade Recipe To Make Protein-Rich Pancakes With Healthy Alternatives

Push-Up Variations You Can Do At Home

Common Mistakes Running Mistakes People Make

Low-Calorie Foods That Keep You Full For Long

Yoga Poses That Help You Get Rid Of Back Pain

Natural Ways To Increase Protein In Your Diet

Managing Excessive Daytime Sleepiness – Tips To Try

How Much Protein Is Too Much?

High Fiber Indian Foods You Should Try

10 Easy Ways To Boost Daily Fiber Intake

Adding Walnut Oil To Your Diet? Benefits You Should Know

Drinks That Soothe Headaches And Migraines

Waist Exercises For More Toned Belly

This Is How Stress Affects Your Heart

Does Digital ‘Brain Rot’ Really Affect Your Health?

Dishes With Fermented Foods To Eat For Your Gut Health

Yoga Poses That Stimulate Good Bowel Health

Weekend Warrior Exercises For Full Body Movement

Weekend Meal Prep Ideas That Will Last You A Weekend

Easy Homemade Healthy Dishes For Long Afternoons

Silent Walking: Mental Health Booster That Keeps You Fit

Dumbbell Exercises You Can Do At Home

These Foods Are Keeping You Awake At Night

Ways to Manage Sugar Cravings

Your Body Doesn’t Want You To Lose Weight – Here's It Resists

High-Protein No Cook Dishes You Should Try

Yoga Poses That Aid In Digestion

Low Calorie Dinner Options For Weight Loss

Cardiac Arrest Vs. Heart Attack: Difference Explained Under 60 Seconds

High Protein Low-Carb Snacks To Have On The Go

Knee Exercises Desk Workers Should Do For Joint Health

Why Do I Feel Sleepy During The Day?

High Protein Early Morning Meals To Keep You Full Till Lunch

In a significant stride toward curbing the spread of vector-borne diseases, India is moving closer to having its first indigenous dengue vaccine. The Indian Council of Medical Research (ICMR), in collaboration with Panacea Biotec, is on track to complete the enrollment of participants for Phase 3 clinical trials by October 2025, according to CNBC-TV18.This crucial phase of testing, launched on August 14, 2024, marks the most advanced stage yet for the vaccine’s development. The multi-center, double-blind, randomised, placebo-controlled study is designed to assess the vaccine’s efficacy, safety, and long-term immunogenicity. So far, over 70% of the targeted 10,335 participants have been enrolled across 20 medical centers nationwide, according to CNBC-TV18 sources.Two-Year Follow-Up Required Before Regulatory SubmissionOnce participant enrollment is completed, each subject will be monitored for a two-year follow-up period. This extended observation window, considered critical for evaluating the vaccine's long-term safety and effectiveness, is expected to conclude by the end of 2027.According to CNBC-TV18, sources familiar with the development confirmed, “The enrollment process is progressing smoothly, and no safety concerns have been reported so far.”Only after the follow-up period ends and the data are thoroughly analyzed will the findings be submitted to the Central Drugs Standard Control Organization (CDSCO) for regulatory review and potential market authorization. “If the vaccine demonstrates acceptable efficacy and a clean safety profile, it could then be considered for regulatory approval and subsequent launch,” CNBC-TV18 reported, quoting official sources.ALSO READ: Dengue On The Rise: How Climate And Geography Are Shaping A Growing ThreatNational-Scale Trial Across Premier InstitutionsThe Phase 3 trial is being carried out at reputed medical institutions located in major cities including Chennai, Pune, Hyderabad, Bengaluru, New Delhi, and Kolkata. According to CNBC-TV18, the study protocol stipulates a comprehensive two-year post-vaccination follow-up. The final data from this period will be crucial in determining the vaccine’s fate in the Indian market.A Single-Dose Vaccine: What Is It All About?What sets this vaccine apart from global counterparts is its single-dose formulation. This is expected to ease the logistical and financial challenges of mass immunization in dengue-endemic areas. Unlike international vaccines like Sanofi’s Dengvaxia and Takeda’s QDENGA—which require multiple doses and have limitations in efficacy across different dengue virus serotypes—India’s homegrown candidate offers a potentially more accessible and broadly applicable alternative.Earlier phases of clinical evaluation, including Phase 1 and Phase 2 trials conducted in India, had already received regulatory clearance from CDSCO. These trials showed that the vaccine was both safe and capable of eliciting a strong immune response.“India’s first dengue vaccine candidate has shown encouraging results so far. Phase 1 and 2 trials confirmed that the vaccine is safe and induces a protective immune response. We’re hopeful that Phase 3 will bring us closer to a much-needed tool in dengue prevention,” CNBC-TV18 reported, citing official sources.YOU MAY LIKE: India’s First Indigenous Dengue Vaccine Coming Soon; What To Expect?A Vital Step for a Country with High Dengue BurdenIndia continues to suffer from seasonal dengue outbreaks, with thousands of hospitalizations each year placing strain on public health infrastructure. The World Health Organization estimates about 390 million dengue infections occur globally each year, with India accounting for a significant portion. With no specific antiviral treatment available, prevention through vaccination and vector control remains the most effective strategy.As per current projections, enrollment will wrap up by October 2025, followed by a two-year follow-up until the end of 2027. Only after this can ICMR and Panacea Biotec submit their formal application for market authorization, CNBC-TV18 noted.If the vaccine passes regulatory scrutiny, it could revolutionize dengue control efforts not only in India but also in other low- and middle-income countries grappling with high disease burdens and limited access to effective vaccines.

india’s first dengue vaccine nears final trial stage

Kang Seo-ha dies at 31 due to stomach cancer

'Jaws' Star Richard Dreyfuss Skips Fan Event After Being Diagnosed With Severe Bronchitis, Know What It Is

'jaws' star richard dreyfuss skips fan event after being diagnosed with severe bronchitis, know what it is

TFC Star Tsubasa Endoh Announces Retirement After Leukemia Battle

tfc star tsubasa endoh announces retirement after leukemia battle

Health & Wellness

'I Thought It Was Something I Ate', Woman Got Diagnosed With Stage 4 Ovarian Cancer After A Routine Ultrasound Revealed Terminal Illness

'i thought it was something i ate', woman got diagnosed with stage 4 ovarian cancer after a routine ultrasound revealed terminal illness

Nutrition

Increase Risk Of Aggressive Brain Cancer Linked To Common Sweetener Used All Over The World

increase risk of aggressive brain cancer linked to common sweetener used all over the world

South Korean actress <span>Kang</span> Seo-ha, known for her performances in K-dramas like <em>First Love Again</em> and <em>The Flower in Prison</em> passed away at the age of 31 after a long battle with <span>stomach cancer</span>. Her family also confirmed the news on Monday. 

Kang's family took to Instagram, and posted a video along with a long note in remembrance of her.

“I still can’t believe it, unnie. Even while enduring such immense pain, you worried about those around you and about me. Even though you couldn’t eat for months, you insisted on paying for my meals with your own card and never let me skip a meal. My angel, who left us far too soon. Even as you endured everything with painkillers, you said you were grateful that it wasn’t worse, and I felt truly ashamed. My dear sister, you went through so much. I hope you are only happy and free from pain where you are now,” the note read.

A memorial service is also being organized at Seoul St Mary's Hospital and the funeral procession is scheduled at 7.40am on July 16 (KST).

<h4>Kang Seo Ha's <span rel="noindex">Cancer</span></h4>

It was in 2024 that Kang was diagnosed with advanced stomach cancer. As per reports, she had stage IV stomach cancer and underwent treatment, including multiple rounds of chemotherapy, while she continued to fulfill her professional commitments. However, in mid-2025, her health rapidly declined, leading to her death. 

As per the National Cancer Institute, US, cancer stage describes the extent of cancer in the body, which includes the size of the tumor, whether it has spread, and how far has it spread from where it was first formed.

In stage IV stomach cancer, which Kang too was suffering from, the cancer spreads to other body parts, mostly lungs, liver, distant lymph nodes, and the tissue that lines the abdomen wall. 

Stage IV stomach cancer, also known as metastatic stomach cancer, occurs when cancer cells spread from the stomach to other parts of the body through the lymphatic system or bloodstream. The new tumors are still made up of stomach cancer cells, not cells from the organs they’ve reached. So, if the cancer spreads to the lungs, it's still considered stomach cancer — not lung cancer — and is referred to as metastatic stomach cancer.

The National Cancer Institute, US, notes that stomach cancer starts in the cells lining the stomach. There are various types of stomach cancers including:

<strong>Adenocarcinoma </strong>of the stomach, which begins in the mucus-producing cells in the innermost lining of the stomach. Nearly all stomach cancers are adenocarcinomas.

<strong>Gastroesophageal junction adenocarcinoma </strong>(GEJ) is a cancer that forms in the area where the esophagus meets the gastric cardia. GEJ may be treated similarly to stomach cancer or esophageal cancer.

<strong>Gastrointestinal neuroendocrine tumors </strong>are cancers that begin in neuroendocrine cells (a type of cell that is like a nerve cell and a hormone-making cell) that line the gastrointestinal tract.

<strong>Gastrointestinal stromal tumors </strong>(GIST) begin in nerve cells that are found in the wall of the stomach and other digestive organs. GIST is a type of soft tissue sarcoma. 

<strong>Primary gastric lymphoma</strong> is a type of non-Hodgkin lymphoma that forms in the stomach. Most primary gastric lymphomas are either mucosa-associated lymphoid tissue (MALT) gastric lymphoma or diffuse large B-cell lymphoma of the stomach. 

kang sea ha

stomach cancer

kang

cancer

south korean actress passes away

South Korean actress Kang Seo-ha, known for her performances in K-dramas like First Love Again and The Flower in Prison passed away at the age of 31 after a long battle with stomach cancer. Her family also confirmed the news on Monday. Kang's family took to Instagram, and posted a video along with a long note in remembrance of her.“I still can’t believe it, unnie. Even while enduring such immense pain, you worried about those around you and about me. Even though you couldn’t eat for months, you insisted on paying for my meals with your own card and never let me skip a meal. My angel, who left us far too soon. Even as you endured everything with painkillers, you said you were grateful that it wasn’t worse, and I felt truly ashamed. My dear sister, you went through so much. I hope you are only happy and free from pain where you are now,” the note read.A memorial service is also being organized at Seoul St Mary's Hospital and the funeral procession is scheduled at 7.40am on July 16 (KST).        View this post on Instagram            A post shared by 은 (@feb.eun)]]> Kang Seo Ha's CancerIt was in 2024 that Kang was diagnosed with advanced stomach cancer. As per reports, she had stage IV stomach cancer and underwent treatment, including multiple rounds of chemotherapy, while she continued to fulfill her professional commitments. However, in mid-2025, her health rapidly declined, leading to her death. As per the National Cancer Institute, US, cancer stage describes the extent of cancer in the body, which includes the size of the tumor, whether it has spread, and how far has it spread from where it was first formed.In stage IV stomach cancer, which Kang too was suffering from, the cancer spreads to other body parts, mostly lungs, liver, distant lymph nodes, and the tissue that lines the abdomen wall. Stage IV stomach cancer, also known as metastatic stomach cancer, occurs when cancer cells spread from the stomach to other parts of the body through the lymphatic system or bloodstream. The new tumors are still made up of stomach cancer cells, not cells from the organs they’ve reached. So, if the cancer spreads to the lungs, it's still considered stomach cancer — not lung cancer — and is referred to as metastatic stomach cancer.Stomach Cancer And Its TypesThe National Cancer Institute, US, notes that stomach cancer starts in the cells lining the stomach. There are various types of stomach cancers including:Adenocarcinoma of the stomach, which begins in the mucus-producing cells in the innermost lining of the stomach. Nearly all stomach cancers are adenocarcinomas.Gastroesophageal junction adenocarcinoma (GEJ) is a cancer that forms in the area where the esophagus meets the gastric cardia. GEJ may be treated similarly to stomach cancer or esophageal cancer.Gastrointestinal neuroendocrine tumors are cancers that begin in neuroendocrine cells (a type of cell that is like a nerve cell and a hormone-making cell) that line the gastrointestinal tract.Gastrointestinal stromal tumors (GIST) begin in nerve cells that are found in the wall of the stomach and other digestive organs. GIST is a type of soft tissue sarcoma. Primary gastric lymphoma is a type of non-Hodgkin lymphoma that forms in the stomach. Most primary gastric lymphomas are either mucosa-associated lymphoid tissue (MALT) gastric lymphoma or diffuse large B-cell lymphoma of the stomach. 

kang seo-ha, south korean actress dies at 31 after battling stage iv stomach cancer

Child Dies Of Measles In UK Hospital As Health Officials Warn Of Rapid Community Spread

child dies of measles in uk hospital as health officials warn of rapid community spread

Measles Death In Liverpool Highlights Vaccine Urgency For Children: Here's What Parents Need To know

liverpool measles death alerted urgency around child mmr vaccines: here's all that you need to know

Pneumonic Plague Death Raises Alarm, Can Prairie Dogs Be The Cause Of It?

pneumonic plague death raises alarm, can prairie dogs be the cause of it?

The Marburg Virus Is Back In Focus Thanks To A Ugandan Scientist, Here's What We Know So Far

the marburg virus is back in focus thanks to a ugandan scientist, here's what we know so far

With the world coping with various bacterial infections, in Australia, it is the season of <span>meningococcal</span> disease. Last month, two Tasmanian women were hospitalized with invasive meningococcal disease, which has brought the numbers to 48.

The cases are showing an uptick, and health authorities are now urging people to watch for symptoms and to check whether they are eligible for vaccination.

According to the Australian Government Department of Health, Disability and Ageing, meningococcal disease is a contagious disease caused by the bacteria Neisseria meningitidis, which is also known as the meningococcal bacteria. It can develop quickly and could be fatal if not treated. Anyone with a suspected meningococcal infection needs to see their doctor immediately.

The official government website of Australia notes: "Meningococcal disease is a medical emergency. It can kill within hours, so early diagnosis and treatment are vital. Do not wait for the purple rash to appear, as that is a late stage of the disease"

However, the ray of hope is that this disease is vaccine-preventable.

The Australian Government's Healthdirect notes that the common symptoms of this disease include:

<ul><li>Fever</li><li>Purple rash</li><li>Meningitis</li><li>Sepsis</li><li>Headache</li><li>Neck stiffness</li><li>Light sensitivity</li><li>Nausea and vomiting</li><li>Loss of appetite</li><li>Drowsiness and confusion</li><li>Leg pain or other muscle or joint aches and pains</li></ul>

In babies or young children, the following can be the symptoms:

<ul><li>difficulty feeding or reduced feeds</li><li>irritability</li><li>tiredness and floppiness</li><li>seizures</li><li>having a high-pitched cry</li><li>having a bulging fontanelle (the soft spot on the top of their head)</li><li>pale or mottled skin</li></ul>

The disease can live in the nose and throat of many healthy people and could spread through coughing, sneezing, sharing eating or drinking utensils, and by kissing.

Complication with the disease can also lead to:

<ul><li>limb differences, or losing a limb</li><li>skin scarring</li><li>hearing loss</li><li>blindness</li><li>learning difficulties</li><li>brain damage</li></ul><h4>Vaccination</h4>

There are different vaccines that treat the different types of this disease, including A, B, C, W, and Y. The vaccination meningococcal B and meningococcal ACWY can be taken at 6 weeks of age.

The MenACWY vaccine is a conjugate vaccine, which means it combines sugars from the outer coating of the bacteria with a protein. This helps trigger a stronger immune response, particularly in young infants.

In contrast, the MenB vaccine doesn’t use the sugar capsule. Instead, it contains four different proteins taken from the surface of the meningococcal B bacteria.

One should speak to a doctor if they have not been vaccinated at a younger age. The vaccination is recommended for:

<ul><li>babies, children, teenagers and young adults</li><li>Aboriginal and/or Torres Strait Islander people</li><li>young adults who live in close quarters or who are current smokers</li><li>travellers</li><li>people who have certain medical conditions that increase their risk of meningococcal disease</li><li>laboratory workers who work with the bacterium that causes meningococcal disease</li></ul>

However, as Healthdirect, an Australian Government's website notes that even with the administration of vaccine, meningococcal disease laboratory workers who work with the bacterium that causes meningococcal disease symptoms may still may linger. In such a case, go visit the hospital for further checks.

Meningococcal

australia health

Meningococcal  disease

Meningococcal  bacteria

seasonal health

With the world coping with various bacterial infections, in Australia, it is the season of meningococcal disease. Last month, two Tasmanian women were hospitalized with invasive meningococcal disease, which has brought the numbers to 48.The cases are showing an uptick, and health authorities are now urging people to watch for symptoms and to check whether they are eligible for vaccination.What Is Meningococcal Disease?According to the Australian Government Department of Health, Disability and Ageing, meningococcal disease is a contagious disease caused by the bacteria Neisseria meningitidis, which is also known as the meningococcal bacteria. It can develop quickly and could be fatal if not treated. Anyone with a suspected meningococcal infection needs to see their doctor immediately.The official government website of Australia notes: "Meningococcal disease is a medical emergency. It can kill within hours, so early diagnosis and treatment are vital. Do not wait for the purple rash to appear, as that is a late stage of the disease"However, the ray of hope is that this disease is vaccine-preventable.What Are The Common Symptoms?The Australian Government's Healthdirect notes that the common symptoms of this disease include:FeverPurple rashMeningitisSepsisHeadacheNeck stiffnessLight sensitivityNausea and vomitingLoss of appetiteDrowsiness and confusionLeg pain or other muscle or joint aches and painsIn babies or young children, the following can be the symptoms:difficulty feeding or reduced feedsirritabilitytiredness and floppinessseizureshaving a high-pitched cryhaving a bulging fontanelle (the soft spot on the top of their head)pale or mottled skinThe disease can live in the nose and throat of many healthy people and could spread through coughing, sneezing, sharing eating or drinking utensils, and by kissing.Complication with the disease can also lead to:limb differences, or losing a limbskin scarringhearing lossblindnesslearning difficultiesbrain damageVaccinationThere are different vaccines that treat the different types of this disease, including A, B, C, W, and Y. The vaccination meningococcal B and meningococcal ACWY can be taken at 6 weeks of age.The MenACWY vaccine is a conjugate vaccine, which means it combines sugars from the outer coating of the bacteria with a protein. This helps trigger a stronger immune response, particularly in young infants.In contrast, the MenB vaccine doesn’t use the sugar capsule. Instead, it contains four different proteins taken from the surface of the meningococcal B bacteria.One should speak to a doctor if they have not been vaccinated at a younger age. The vaccination is recommended for:babies, children, teenagers and young adultsAboriginal and/or Torres Strait Islander peopleyoung adults who live in close quarters or who are current smokerstravellerspeople who have certain medical conditions that increase their risk of meningococcal diseaselaboratory workers who work with the bacterium that causes meningococcal diseaseHowever, as Healthdirect, an Australian Government's website notes that even with the administration of vaccine, meningococcal disease laboratory workers who work with the bacterium that causes meningococcal disease symptoms may still may linger. In such a case, go visit the hospital for further checks.

australia sees rise in meningococcal disease: what you need to know about symptoms and vaccination

WHO Recommends New HIV Twice-Yearly Shot Amid Fund Cuts; What Are The Big Challenges The Drug Faces?

HIV Vaccine Research In South Africa Crumbles As U.S. Pulls Funding

hiv vaccine research in south africa crumbles as u.s. pulls funding

More than 14 million children worldwide did not receive a single routine vaccine last year, according to a joint report released Tuesday by the World Health Organization (WHO) and UNICEF. The number remains unchanged from 2023, highlighting a worrying stagnation in global immunization efforts.

The annual estimate of global vaccine coverage found that 89% of children under one year received the first dose of the diphtheria, tetanus, and pertussis (DTP) vaccine in 2024 — the same as in the previous year. However, only 85% completed the full three-dose series, a slight rise from 84% in 2023.

Despite modest gains, officials warn that progress is faltering due to geopolitical shifts, humanitarian crises, and rising vaccine misinformation.

<h4>Foreign Aid Cuts Threaten Vaccine Programs</h4>

The report comes amid a sharp pullback in international health funding, particularly from the United States. Earlier this year, President Trump officially withdrew U.S. membership from the WHO, suspended most humanitarian aid, and moved to shut down the U.S. Agency for International Development (USAID).

<h4>Further compounding the issue, U.S. Health </h4>

Secretary Robert F. Kennedy Jr., a known vaccine skeptic, recently announced the withdrawal of billions of dollars pledged to Gavi, the global vaccine alliance. He accused the group of “ignoring the science,” despite overwhelming evidence that vaccines are safe and effective.

These decisions are expected to significantly impact global vaccine rollouts, especially in low-income countries.

Nine countries accounted for 52% of all unvaccinated children in 2024. These include:

<ul><li>Nigeria</li><li>India</li><li>Sudan</li><li>Democratic Republic of Congo</li><li>Ethiopia</li><li>Indonesia</li><li>Yemen</li><li>Afghanistan</li><li>Angola</li></ul>

Among them, Sudan reported the lowest coverage for DTP vaccines — a reflection of the country’s ongoing conflict and humanitarian crisis. WHO officials said war, displacement, and weak health systems are major barriers to <span>vaccination</span>.

“Access to vaccines remains deeply unequal,” said WHO Director-General Tedros Adhanom Ghebreyesus. “Drastic cuts in aid, coupled with misinformation about vaccine safety, threaten to unwind decades of progress.”

<h4>Measles on the Rise Amid Lagging Coverage</h4>

The report showed a slight improvement in global measles vaccination rates, with 76% of children receiving both doses — up from previous years. But experts warn this is far below the 95% threshold needed to prevent outbreaks of this highly contagious disease.

In 2024 alone, 60 countries reported large measles outbreaks. The United States is currently experiencing its worst measles outbreak in over 30 years, while Europe recorded 125,000 cases, more than double the 2023 count.

Last week, a child in Liverpool, UK, died of measles. Despite ongoing public awareness campaigns, only 84% of children in the U.K. are vaccinated against the disease.

<h4>“It’s Never Too Late to Be Vaccinated”</h4>

Experts are urging families and governments to act. “It is hugely concerning, but not at all surprising, that we are continuing to see outbreaks of measles,” said Helen Bradford, a children’s health professor at University College London. “The only way to stop measles spreading is with vaccination. It is never too late to be vaccinated — even as an adult.”

us news

us trends

WHO study

vaccination

children unvaccinated

14 million children unvaccinaed

More than 14 million children worldwide did not receive a single routine vaccine last year, according to a joint report released Tuesday by the World Health Organization (WHO) and UNICEF. The number remains unchanged from 2023, highlighting a worrying stagnation in global immunization efforts.The annual estimate of global vaccine coverage found that 89% of children under one year received the first dose of the diphtheria, tetanus, and pertussis (DTP) vaccine in 2024 — the same as in the previous year. However, only 85% completed the full three-dose series, a slight rise from 84% in 2023.Despite modest gains, officials warn that progress is faltering due to geopolitical shifts, humanitarian crises, and rising vaccine misinformation.Foreign Aid Cuts Threaten Vaccine ProgramsThe report comes amid a sharp pullback in international health funding, particularly from the United States. Earlier this year, President Trump officially withdrew U.S. membership from the WHO, suspended most humanitarian aid, and moved to shut down the U.S. Agency for International Development (USAID).Further compounding the issue, U.S. Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic, recently announced the withdrawal of billions of dollars pledged to Gavi, the global vaccine alliance. He accused the group of “ignoring the science,” despite overwhelming evidence that vaccines are safe and effective.These decisions are expected to significantly impact global vaccine rollouts, especially in low-income countries.Who's Being Left Behind?Nine countries accounted for 52% of all unvaccinated children in 2024. These include:NigeriaIndiaSudanDemocratic Republic of CongoEthiopiaIndonesiaYemenAfghanistanAngolaAmong them, Sudan reported the lowest coverage for DTP vaccines — a reflection of the country’s ongoing conflict and humanitarian crisis. WHO officials said war, displacement, and weak health systems are major barriers to vaccination.“Access to vaccines remains deeply unequal,” said WHO Director-General Tedros Adhanom Ghebreyesus. “Drastic cuts in aid, coupled with misinformation about vaccine safety, threaten to unwind decades of progress.”Measles on the Rise Amid Lagging CoverageThe report showed a slight improvement in global measles vaccination rates, with 76% of children receiving both doses — up from previous years. But experts warn this is far below the 95% threshold needed to prevent outbreaks of this highly contagious disease.In 2024 alone, 60 countries reported large measles outbreaks. The United States is currently experiencing its worst measles outbreak in over 30 years, while Europe recorded 125,000 cases, more than double the 2023 count.Last week, a child in Liverpool, UK, died of measles. Despite ongoing public awareness campaigns, only 84% of children in the U.K. are vaccinated against the disease.“It’s Never Too Late to Be Vaccinated”Experts are urging families and governments to act. “It is hugely concerning, but not at all surprising, that we are continuing to see outbreaks of measles,” said Helen Bradford, a children’s health professor at University College London. “The only way to stop measles spreading is with vaccination. It is never too late to be vaccinated — even as an adult.”

over 14 million children miss out on vaccines amid aid cuts and rising misinformation

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

India’s First Dengue Vaccine Nears Final Trial Stage

Quick Stories

Kang Seo-ha, South Korean Actress Dies At 31 After Battling Stage IV Stomach cancer

Australia Sees Rise In Meningococcal Disease: What You Need To Know About Symptoms And Vaccination

Over 14 Million Children Miss Out On Vaccines Amid Aid Cuts And Rising Misinformation

Health Conditions A-Z

Kang Seo-ha, South Korean Actress Dies At 31 After Battling Stage IV Stomach cancer

Australia Sees Rise In Meningococcal Disease: What You Need To Know About Symptoms And Vaccination

Over 14 Million Children Miss Out On Vaccines Amid Aid Cuts And Rising Misinformation